{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:15:21Z","timestamp":1791818121861,"version":"4.3.4"},"reference-count":114,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.addr.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T18:15:45Z","timestamp":1331403345000},"page":"1205-1219","source":"Crossref","is-referenced-by-count":227,"title":["Development of macromolecular prodrug for rheumatoid arthritis"],"prefix":"10.1016","volume":"64","author":[{"given":"Fang","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-dong","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2012.03.006_bb0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543776.18.7.723","article-title":"The development of novel therapies for rheumatoid arthritis","volume":"18","author":"Quan","year":"2008","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.addr.2012.03.006_bb0010","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s11095-008-9683-3","article-title":"Synthesis and evaluation of a well-defined HPMA copolymer\u2013dexamethasone conjugate for effective treatment of rheumatoid arthritis","volume":"25","author":"Liu","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(05)70201-5","article-title":"The epidemiology of rheumatoid arthritis","volume":"27","author":"Gabriel","year":"2001","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.addr.2012.03.006_bb0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/art.23538","article-title":"Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US","volume":"59","author":"Allaire","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0025","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/art.22979","article-title":"The widening mortality gap between rheumatoid arthritis patients and the general population","volume":"56","author":"Gonzalez","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0030","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":"Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0035","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/40.9.978","article-title":"Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate","volume":"40","author":"Richards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.addr.2012.03.006_bb0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ard.2003.009944","article-title":"Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II athritis","volume":"63","author":"Metselaar","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0045","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/ard.2009.108985","article-title":"Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis","volume":"68","author":"Rauchhaus","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0050","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/ar2889","article-title":"Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment","volume":"11","author":"Rauchhaus","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2012.03.006_bb0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2011.02.060","article-title":"Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis","volume":"416","author":"Hofkens","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","article-title":"Liposomal drug formulations in the treatment of rheumatoid arthritis","volume":"8","author":"van den Hoven","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ni1205-1179","article-title":"Dampening inflammation","volume":"6","author":"Henson","year":"2005","journal-title":"Nat. Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2012.03.006_bb0070","doi-asserted-by":"crossref","first-page":"ii60","DOI":"10.1136\/ard.62.suppl_2.ii60","article-title":"Angiogenesis as a target in rheumatoid arthritis","volume":"62","author":"Koch","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0075","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/art.1780241215","article-title":"Permeability of rheumatoid and normal human synovium to specific plasma proteins","volume":"24","author":"Levick","year":"1981","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0080","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0085","doi-asserted-by":"crossref","first-page":"R118","DOI":"10.1186\/ar2326","article-title":"Increased lymphangiogenesis in joints of mice with inflammatory arthritis","volume":"9","author":"Zhang","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2012.03.006_bb0090","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/art.24764","article-title":"Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis","volume":"60","author":"Guo","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0095","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1023\/B:PHAM.0000045232.18134.e9","article-title":"The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study","volume":"21","author":"Wang","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0100","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","article-title":"Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis","volume":"170","author":"Wunder","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2012.03.006_bb0105","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/bm100578c","article-title":"Syntheses of click PEG\u2013dexamethasone conjugates for the treatment of rheumatoid arthritis","volume":"11","author":"Liu","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2012.03.006_bb0110","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","article-title":"Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics","volume":"61","author":"Gaspar","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2012.03.006_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/rheumatology\/37.9.937","article-title":"Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment","volume":"37","author":"Hawkey","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/j.1552-4604.1986.tb02905.x","article-title":"Ibuprofen kinetics in plasma and synovial fluid of arthritic patients","volume":"26","author":"Gallo","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2012.03.006_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009748109095329","article-title":"Ibuprofen levels in serum and synovial fluid","volume":"39","author":"M\u00e4kel\u00e4","year":"1981","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"10.1016\/j.addr.2012.03.006_bb0130","series-title":"High molecular prodrug derivatives of anti-inflammatory drugs","author":"Larsen","year":"1989"},{"key":"10.1016\/j.addr.2012.03.006_bb0135","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-007-9449-3","article-title":"Stability in plasmas of various species of HPMA copolymer\u2013PGE1 conjugates","volume":"24","author":"Pan","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0140","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0145","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/ard.2003.013748","article-title":"Methotrexate (MTX) and albumin coupled with MTX (MTX\u2013HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo","volume":"63","author":"Fiehn","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0150","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/ard.2007.086843","article-title":"Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis","volume":"67","author":"Fiehn","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0155","series-title":"Application of biotin-mediated targeting","author":"Russell-Jones","year":"2004"},{"key":"10.1016\/j.addr.2012.03.006_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2012.03.006_bb0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00001813-199708000-00006","article-title":"The loading rate determines tumor targeting properties of methotrexate\u2013albumin conjugates in rats","volume":"8","author":"Stehle","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.addr.2012.03.006_bb0170","first-page":"753","article-title":"Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society","volume":"5","author":"Hartung","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10637-006-8221-6","article-title":"Phase II study of MTX\u2013HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma","volume":"24","author":"Bolling","year":"2006","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.addr.2012.03.006_bb0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-63-1-109","article-title":"The mechanism of hypoalbuminemia in rheumatoid arthritis","volume":"63","author":"Wilkinson","year":"1965","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2012.03.006_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/ard.30.3.265","article-title":"Albumin metabolism in rheumatoid arthritis","volume":"30","author":"Ballantyne","year":"1971","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/nl0479987","article-title":"Super pH-sensitive multifunctional polymeric micelle","volume":"5","author":"Lee","year":"2005","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2012.03.006_bb0195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/bc9005656","article-title":"Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release","volume":"21","author":"Chen","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0200","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/bc0499174","article-title":"Synthesis and characterization of dextran\u2013peptide\u2013methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX","volume":"15","author":"Chau","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0205","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.1993.207","article-title":"Activity of type-IV collagenases in benign and malignant breast disease","volume":"67","author":"Davies","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2012.03.006_bb0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/bjc.1994.30","article-title":"Matrix metalloproteinase-9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia","volume":"69","author":"Hamdy","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2012.03.006_bb0215","first-page":"439","article-title":"Increased expression of the Mr 72, 000 type-IV collagenase in human colonic adenocarcinoma","volume":"51","author":"Levy","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ijc.2910580110","article-title":"Expression and activity of MMPs and their regulators in ovarian-cancer","volume":"58","author":"Naylor","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2012.03.006_bb0225","first-page":"5365","article-title":"Levels of matrix metalloproteases in bladder-cancer correlate with tumor grade and invasion","volume":"53","author":"Davies","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0230","first-page":"239","article-title":"Augmentation of type-IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast-carcinoma progression","volume":"4","author":"Derrico","year":"1991","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.addr.2012.03.006_bb0235","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2741\/1817","article-title":"Matrix metalloproteinases: role in arthritis","volume":"11","author":"Burrage","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.addr.2012.03.006_bb0240","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0037-1613578","article-title":"Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma","volume":"89","author":"Kuyvenhoven","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.addr.2012.03.006_bb0245","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.biomaterials.2006.07.046","article-title":"The development of folate\u2013PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats","volume":"28","author":"Chandrasekar","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2012.03.006_bb0250","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.09.023","article-title":"Dendrimers as versatile platform in drug delivery applications","volume":"71","author":"Svenson","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0255","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/bc0000583","article-title":"Synthesis of polyamidoamine dendrimers having poly-(ethylene glycol) grafts and their ability to encapsulate anticancer drugs","volume":"11","author":"Kojima","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0260","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1021\/bm201196p","article-title":"Intrinsically fluorescent PAMAM dendrimer as gene carrier and nanoprobe for nucleic acids delivery: bioimaging and transfection study","volume":"12","author":"Tsai","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2012.03.006_bb0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.nano.2010.10.008","article-title":"Poly(amidoamine) dendrimer\u2013erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation","volume":"7","author":"Bosnjakovic","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2012.03.006_bb0270","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/bc900228m","article-title":"PAMAM\u2013RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma","volume":"20","author":"Waite","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0275","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1021\/jm0401863","article-title":"Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy","volume":"48","author":"Majoros","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0280","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.bmc.2011.03.019","article-title":"Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer\u2013methotrexate conjugate as a potential anticancer agent","volume":"19","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0285","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/bc900217h","article-title":"RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies","volume":"20","author":"McNerny","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0290","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.21719","article-title":"Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis","volume":"54","author":"Koning","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0295","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L","article-title":"Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis","volume":"42","author":"Matsushita","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2009.05367.x","article-title":"Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis","volume":"1193","author":"Todoerti","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2012.03.006_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mce.2007.05.014","article-title":"Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index","volume":"275","author":"Sch\u00e4cke","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.addr.2012.03.006_bb0310","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","article-title":"Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists","volume":"275","author":"Stahn","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.addr.2012.03.006_bb0315","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1023\/A:1016069315423","article-title":"Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity","volume":"13","author":"Timofeevski","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0168-3659(00)00234-0","article-title":"Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes","volume":"68","author":"Mehvar","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2012.03.006_bb0325","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/jps.21161","article-title":"Synthesis and in vitro characterization of novel dextran\u2013methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates","volume":"97","author":"Penugonda","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2012.03.006_bb0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2011.03.004","article-title":"Kinetic analysis of in vitro and in vivo release of prednisolone from the conjugate of glycol-chitosan and succinyl-prednisolone","volume":"410","author":"Onishi","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2008.08.034","article-title":"Synthesis and evaluation of dextran\u2013budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis","volume":"365","author":"Varshosaz","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0340","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/bc800526z","article-title":"Effects of branching architecture and linker on the activity of hyperbranched polymer\u2013drug conjugates","volume":"20","author":"Perumal","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2012.03.006_bb0345","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2010.07.030","article-title":"In vivo efficacy of dendrimer\u2013methylprednisolone conjugate formulation for the treatment of lung inflammation","volume":"399","author":"Inapagolla","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2008.12.001","article-title":"Dexamethasone\u2013pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers","volume":"135","author":"Keely","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2012.03.006_bb0355","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.addr.2008.08.002","article-title":"Hydrogel nanoparticles in drug delivery","volume":"60","author":"Hamidi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2012.03.006_bb0360","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-3057(73)90063-3","article-title":"Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization","volume":"9","author":"Kope\u010dek","year":"1973","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.addr.2012.03.006_bb0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0142-9612(84)90062-0","article-title":"Controlled biodegradability of polymers\u2014a key to drug delivery systems","volume":"5","author":"Kope\u010dek","year":"1984","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2012.03.006_bb0370","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0939-6411(00)00075-8","article-title":"HPMA copolymer\u2013anticancer drug conjugates: design, activity, and mechanism of action","volume":"50","author":"Kope\u010dek","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0375","first-page":"3980","article-title":"Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice","author":"Peterson","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0380","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jbm.820070206","article-title":"New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood","volume":"7","author":"Kope\u010dek","year":"1973","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0385","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF02884085","article-title":"Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers-potential hapten or drug carriers","volume":"28","author":"R\u00edhov\u00e1","year":"1983","journal-title":"Folia Microbiol. (Praha)"},{"key":"10.1016\/j.addr.2012.03.006_bb0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0142-9612(84)90048-6","article-title":"Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice","volume":"5","author":"\u0158\u00edhov\u00e1","year":"1984","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2012.03.006_bb0395","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/jbm.820211106","article-title":"Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats","volume":"21","author":"Seymour","year":"1987","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/macp.1985.020091985103","article-title":"Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers","volume":"9","author":"\u0158\u00edhov\u00e1","year":"1985","journal-title":"Makromol. Chem. Suppl."},{"key":"10.1016\/j.addr.2012.03.006_bb0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2009.10.005","article-title":"Immunogenicity and immunomodulatory properties of HPMA-based polymers","volume":"62","author":"\u0158\u00edhov\u00e1","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2012.03.006_bb0410","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.compositesb.2006.07.007","article-title":"Biocompatibility and immunocompatibility of water-soluble polymers based on HPMA","volume":"38","author":"\u0158\u00edhov\u00e1","year":"2007","journal-title":"Composites Part B"},{"key":"10.1016\/j.addr.2012.03.006_bb0415","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3109\/17453676908989529","article-title":"Synovial pH in rheumatoid kneejoints. I. The effect of synovectomy","volume":"40","author":"Goldie","year":"1969","journal-title":"Acta Orthop. Scand."},{"key":"10.1016\/j.addr.2012.03.006_bb0420","first-page":"2018","article-title":"Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat","volume":"26","author":"Andersson","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0425","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.10185","article-title":"Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis","volume":"46","author":"Konttinen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0430","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1359\/jbmr.2001.16.10.1780","article-title":"Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis","volume":"16","author":"Konttinen","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.addr.2012.03.006_bb0435","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0002-9343(70)80078-X","article-title":"Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis","volume":"49","author":"Falchuk","year":"1970","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2012.03.006_bb0440","first-page":"579","article-title":"Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure","volume":"17","author":"Levick","year":"1990","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0445","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar2106","article-title":"Novel dexamethasone\u2013HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis","volume":"9","author":"Wang","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2012.03.006_bb0450","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/mp100132h","article-title":"Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer\u2013dexamethasone conjugates in adjuvant-induced arthritis rat model","volume":"7","author":"Quan","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0455","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1021\/bi0257080","article-title":"Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors","volume":"41","author":"Wang","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2012.03.006_bb0460","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2009.02.010","article-title":"PEG conjugates in clinical development or use as anticancer agents: an overview","volume":"61","author":"Pasut","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2012.03.006_bb0465","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.2003.03.143","article-title":"A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3weeks in patients with advanced solid malignancies","volume":"21","author":"Rowinsky","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2012.03.006_bb0470","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/1061186X.2010.504271","article-title":"Development of a novel polyethylene glycol\u2013corticosteroid-conjugate with an acid-cleavable linker","volume":"19","author":"Funk","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2012.03.006_bb0475","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar3130","article-title":"Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy","volume":"12","author":"Quan","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2012.03.006_bb0480","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/mp200328t","article-title":"The bone, the joints and the balm of gilead","volume":"8","author":"Wang","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0485","first-page":"329","article-title":"The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing","volume":"35","author":"Bures","year":"1988","journal-title":"Neoplasma"},{"key":"10.1016\/j.addr.2012.03.006_bb0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jcem-72-1-39","article-title":"Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry","volume":"72","author":"Esteban","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2012.03.006_bb0495","first-page":"596","article-title":"Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids","volume":"23","author":"Gudbj\u00f6rnsson","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0500","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/art.1780351107","article-title":"Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis","volume":"35","author":"Chikanza","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0505","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.addr.2012.03.006_bb0510","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update","volume":"44","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2012.03.006_bb0515","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1183\/09031936.93.05080997","article-title":"Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered","volume":"5","author":"Dekhuijzen","year":"1992","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2012.03.006_bb0520","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.addr.2012.03.006_bb0525","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(61)92007-4","article-title":"Biochemical confirmation of collapse due to adrenal failure","volume":"1","author":"Sampson","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2012.03.006_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncprheum0973","article-title":"Rheumatoid arthritis in a mouse?","volume":"5","author":"Firestein","year":"2009","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0535","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/rheumatology\/37.3.314","article-title":"Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation","volume":"37","author":"Hart","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/ar1773","article-title":"Modeling human arthritic diseases in nonhuman primates","volume":"7","author":"Vierboom","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2012.03.006_bb0545","doi-asserted-by":"crossref","first-page":"569068","DOI":"10.1155\/2011\/569068","article-title":"Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy","volume":"2011","author":"Bolon","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.addr.2012.03.006_bb0550","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1073\/pnas.86.7.2374","article-title":"Inflammatory mediator-induced hypothalamic\u2013pituitary\u2013adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats","volume":"86","author":"Sternberg","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2012.03.006_bb0555","first-page":"214","article-title":"Upper limb lymphatic function in inflammatory arthritis","volume":"22","author":"Kiely","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0560","first-page":"1043","article-title":"Upper limb lymphedema associated with polyarthritis of rheumatoid type","volume":"21","author":"Kiely","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2012.03.006_bb0565","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1021\/mp2000555","article-title":"Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates","volume":"8","author":"Ren","year":"2001","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2012.03.006_bb0570","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2010.02.005","article-title":"A multitude of kinases\u2014which are the best targets in treating rheumatoid arthritis?","volume":"36","author":"Lindstrom","year":"2010","journal-title":"Rheum. Dis. Clin. North Am."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X12001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X12001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:13:56Z","timestamp":1742685236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X12001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":114,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0169409X12001020"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2012.03.006","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}